Clinical Trials for Hepatocellular Carcinoma
229 hepatocellular carcinoma trials indexed, 115 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. It begins in the main cells of the liver called hepatocytes. This cancer develops when these cells grow uncontrollably due to genetic mutations or damage to the liver. The underlying biology often involves chronic liver inflammation and scarring, also known as cirrhosis, which can be caused by infections or toxins. Doctors diagnose HCC through a combination of imaging tests like ultrasound, CT scans, and MRIs, along with blood tests that measure liver function and tumor markers such as alpha-fetoprotein (AFP). In some cases, a biopsy may be needed to confirm the diagnosis.
Symptoms of hepatocellular carcinoma may not appear in the early stages. When they do, common signs include abdominal pain or swelling, unexplained weight loss, fatigue, and jaundice, which is yellowing of the skin and eyes. HCC most often affects adults over the age of 50, but younger people with risk factors can also develop it. The highest risk groups include those with chronic hepatitis B or C infections, heavy alcohol use, non-alcoholic fatty liver disease, and exposure to aflatoxins, which are toxins from certain molds. Men are more likely than women to develop HCC, and it is more common in regions with high rates of liver infections.
Hepatocellular carcinoma is a major medical and social concern worldwide. It ranks as the sixth most common cancer globally and is the third leading cause of cancer-related deaths. For example, in 2020, over 800,000 new cases were diagnosed, and the survival rate remains low due to late detection. The economic burden is significant, including costs for treatment, hospital stays, and lost productivity. Early diagnosis and improved therapies are critical because advanced HCC often leads to liver failure and death within months. Understanding this disease helps highlight the need for ongoing research and better care strategies.
The Hepatocellular Carcinoma Treatment Landscape
The first-line treatment for hepatocellular carcinoma depends on the stage of the disease and liver function. Early-stage HCC may be treated with surgical removal of the tumor or liver transplantation, which can offer a chance for long-term survival. For patients not eligible for surgery, local therapies such as ablation or embolization are common. In advanced cases, systemic treatments become necessary. The standard first-line systemic therapy includes targeted drugs like sorafenib and lenvatinib, which work by blocking signals that help cancer cells grow. Treatment is typically tiered based on tumor size, number, and liver health, with the goal to control cancer progression and maintain quality of life.
When first-line treatments fail or are not tolerated, second- and third-line options are available. These include other targeted therapies and immune checkpoint inhibitors, which help the immune system recognize and attack cancer cells. Drugs such as regorafenib and cabozantinib are examples of targeted therapies used in later lines. Immunotherapy agents like nivolumab and pembrolizumab have also been approved for some patients with advanced HCC. These options provide alternatives but often come with varying degrees of effectiveness and side effects. The choice of treatment depends on prior therapies, patient health, and specific tumor characteristics.
Despite advances, there are significant gaps in current treatments for hepatocellular carcinoma. Some patient subgroups, such as those with poor liver function or certain genetic profiles, respond poorly to available drugs. Resistance to targeted therapies often develops, limiting long-term benefits. Side effects like fatigue, diarrhea, and high blood pressure can reduce patients’ ability to continue treatment. Research efforts focus on finding new drug combinations, improving immune therapies, and identifying biomarkers to predict who will respond best. Closing these gaps is essential to improve outcomes for people living with HCC.
Why Clinical Trials Matter for Hepatocellular Carcinoma
Clinical trials offer important opportunities for patients with hepatocellular carcinoma. These studies test new treatments or combinations that are not yet widely available. Patients who join trials may gain access to novel therapies and receive closer medical monitoring throughout the study. According to ClinicalTrials.gov, there are currently 229 hepatocellular carcinoma clinical trials indexed, with 115 actively recruiting participants. This growing number reflects ongoing efforts to find better ways to treat HCC and improve survival rates. Participation also contributes to medical knowledge that may help future patients.
It is important to understand the risks involved with clinical trials. New treatments may not work better than existing options and can have unknown side effects. Some trials include placebo arms where participants do not receive the experimental drug, which may affect expectations. Additional clinic visits, tests, and procedures are often required, which can be time-consuming and stressful. Patients should carefully discuss these factors with their healthcare team to make informed decisions about joining a trial.
The landscape of clinical trial sponsors for hepatocellular carcinoma is diverse. Academic medical centers conduct many early-phase studies to explore basic science and new drugs. Pharmaceutical companies fund later-phase trials to test treatments on larger groups. Cooperative groups, which are networks of hospitals and research centers, also run trials to gather broad data. ClinicalTrials.gov serves as a central registry where patients, caregivers, and doctors can find detailed information about ongoing studies. This transparency helps connect people with trials suited to their needs and supports the advancement of HCC research.
What to Look for in a Hepatocellular Carcinoma Clinical Trial
Clinical trials are divided into phases that show how new treatments are tested. Phase 1 trials focus on safety and finding the right dose. Phase 2 trials look at how well the treatment works and continue safety checks. Phase 3 trials compare the new treatment to the current standard. Phase 4 trials happen after approval to monitor long-term effects. For hepatocellular carcinoma, most trials are in Phase 2, with 70 studies. There are 63 Phase 1 trials, 15 Phase 3 trials, and 32 trials without a specified phase.
When joining a hepatocellular carcinoma trial, patients usually must meet specific inclusion criteria. These can include age limits, often adults 18 or older. Prior treatments may affect eligibility, such as having had surgery, chemotherapy, or other liver-directed therapies. Some trials require certain biomarkers or genetic markers to be present. The stage of cancer is also important; many trials focus on intermediate or advanced stages. Disease duration and liver function tests help determine if a patient can safely participate.
Exclusion criteria help protect patients and ensure accurate results. People with serious other health problems, like heart or kidney disease, might be excluded. Drug interactions are a concern, so some medications may disqualify a patient. Safety thresholds, such as low blood counts or poor liver function, often prevent participation. These rules aim to reduce risks and avoid complications during the trial.
Patients should also think about practical matters before joining a trial. The length of the study can range from a few months to several years. Visit schedules vary: some trials require frequent hospital visits, while others have fewer. Travel to the trial site might be needed, which can be difficult for some patients. It is important to ask the research team questions like: How many visits will I need? What side effects should I expect? Will I have to stop my current treatments? What happens if I want to leave the trial early?
Primary Sources and Further Reading
For reliable information on hepatocellular carcinoma and clinical trials, it is best to consult trusted medical websites. These sources provide up-to-date details on treatments, research studies, and patient support. They can help patients and caregivers understand the options and prepare for discussions with healthcare providers.
- National Cancer Institute: Liver Cancer Treatment
- MedlinePlus: Liver Cancer
- ClinicalTrials.gov: Hepatocellular Carcinoma Trials
- Centers for Disease Control and Prevention: Liver Cancer
Latest Research and Emerging Treatments for Hepatocellular Carcinoma (2026)
Current hepatocellular carcinoma treatment research is focusing on immunotherapy and targeted therapies that may improve survival for patients. One Phase 3 trial is testing a combination of nivolumab and ipilimumab, two immunotherapy drugs that help the immune system recognize and attack cancer cells. This study compares the combination to standard treatments like sorafenib and lenvatinib, which are targeted drugs that block signals cancer cells use to grow. Early data suggests these immune checkpoint inhibitors could offer a new first-line option for advanced liver cancer (NCT04039607).
Another important study is exploring the use of durvalumab and tremelimumab as first-line treatment. Both drugs belong to the immunotherapy class that helps reactivate immune cells to fight tumors. This trial aims to see if this combination can improve outcomes compared to current therapies like sorafenib (NCT03298451). Additionally, researchers are testing immunotherapy with or without stereotactic body radiation therapy, which delivers precise radiation to tumors. Combining immune drugs like atezolizumab or durvalumab with targeted radiation may help patients live longer by attacking cancer in two ways (NCT07166406).
For patients with resectable hepatocellular carcinoma at high risk of recurrence, a study is investigating neoadjuvant treatment with tislelizumab, an immune checkpoint inhibitor, plus lenvatinib. This approach aims to reduce the chance of cancer returning after surgery by shrinking tumors and boosting immune response before the operation (NCT07475026). Radiation therapy research is also ongoing, comparing proton therapy to standard photon therapy to reduce damage to healthy organs while treating liver cancer (NCT03186898). These new drugs for hepatocellular carcinoma and treatment strategies in 2026 reflect ongoing efforts to expand options and improve quality of life for patients facing this disease.
Frequently asked questions about Hepatocellular Carcinoma trials
How do I find Hepatocellular Carcinoma clinical trials?
The authoritative source for Hepatocellular Carcinoma clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 229 hepatocellular carcinoma studies are currently indexed. You can search by entering "hepatocellular carcinoma" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new hepatocellular carcinoma trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Hepatocellular Carcinoma trials in?
Across the 229 hepatocellular carcinoma trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Hepatocellular Carcinoma clinical trials are currently recruiting?
As of the latest scan, 115 hepatocellular carcinoma trials have a "Recruiting" status on ClinicalTrials.gov, out of 229 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting hepatocellular carcinoma trial matches their tracked condition.
Stay informed about hepatocellular carcinoma research
Get a weekly briefing with the trials that matter most.